Browse

A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder

Cited 15 time in Web of Science Cited 17 time in Scopus
Authors
Kim, Chang Yoon; Chung, Seockhoon; Lee, Joon-Noh; Kwon, Jun Soo; Kim, Chul Eung; Jeon, Yang-Whan; Jun, Tae-Youn; Jung, Hee-Yeon; Lee, Min-Soo; Jeong, Bumseok; Kim, Do Hoon
Issue Date
2009-07
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Citation
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY; Vol.24 4; 181-188
Keywords
aripiprazoleefficacyswitchingschizophreniasafety
Abstract
The objectives of this 12-week multicenter open-label switching study were to evaluate the overall clinical efficacy, safety, and tolerability of aripiprazole in stable patients with schizophrenia or schizoaffective disorder, and to assess, in a naturalistic setting, whether such patients experience symptom worsening when switched from D(2) receptor antagonists to aripiprazole (a D(2) receptor partial agonist). Patients with schizophrenia or schizoaffective disorder in a symptomatically stable state were randomized to aripiprazole or standard-of-care antipsychotics. The Clinical Global Impression (CGI), Positive and Negative Syndrome Scale, and Investigator`s Assessment Questionnaire were used monthly. The Udvalg for Kliniske Undersogelser side-effect rating scale scores and treatment emergent adverse events were recorded to assess the safety and tolerability of switching to aripiprazole from other antipsychotics. A total of 292 patients were randomly assigned to receive aripiprazole (N=245) or non-aripiprazole antipsychotics (N=47). Mean CGI-Improvement score at 12 weeks was 3.56 +/- 1.29 (95% confidence interval: 3.39-3.73) in the aripiprazole group, indicating that aripiprazole was effective in treating schizophrenic patients. Aripiprazole treatment resulted in improvement from baseline on all efficacy outcome measures, including Positive and Negative Syndrome Scale total, positive, negative, and general subscale, and CGI-Severity scores. In addition, after aripiprazole treatment, the remission rate was increased from 43.9% at baseline to 51.7% at 12 weeks. The proportion of patients with symptom worsening at 12 weeks was low (12.4%). Both Investigator`s Assessment Questionnaire and Udvalg for Kliniske Undersogelser scores showed that there were fewer prolactin-related adverse events in the aripiprazole group than in the standard-of-care antipsychotics group (P<0.05). There were no significant between-group differences in time to failure to maintain remission and time to dropout. In the naturalistic setting, symptomatically stable outpatients with schizophrenia who were switched to aripiprazole showed clinically meaningful treatment benefits. The majority of patients was successfully switched from other antipsychotics without serious symptom exacerbation or adverse events over a course of 12 weeks. Int Clin Psychopharmacol 24:181-188 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
ISSN
0268-1315
Language
English
URI
http://hdl.handle.net/10371/78590
DOI
https://doi.org/10.1097/YIC.0b013e32832c25d7
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Psychiatry (정신과학전공)Journal Papers (저널논문_정신과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse